TIDMNGG
RNS Number : 9854N
NextGen Group PLC
09 September 2011
NextGen Group PLC
Interim Results to 30 June 2011
NextGen Group plc, (AIM: NGG, 'the Group', 'NextGen'), a
provider of biomarker discovery and qualification (testing)
services using mass spectrometry technology, announces its interim
results for the six months ended 30 June 2011. NextGen's biomarker
services are provided through its wholly owned US-subsidiary,
NextGen Sciences Inc. (NGS).
Highlights
-- New business plan written to focus on scalable and profitable
products that will enable the business to increase its therapeutic
relevance as a route to promoting market access and growing sales.
Core product focus on protein biomarker discovery, assay
development and biomarker qualification
-- Operational restructure of NGS completed to enable effective
development and launch of products defined with the business
plan
-- Focus on Oncology and CNS (central nervous system)
therapeutic areas. The first stages in developing two new product
lines have been achieved.
o plasmadiscovery41 assay panel for biomarker discovery and
qualification (testing) targeting oncology (prostate, colorectal
and breast cancer as focus areas) was launched in March 2011.
o csfdiscovery43 assay panel for biomarker discovery and
qualification targeting CNS diseases (Alzheimer's, Parkinson's and
multiple sclerosis as focus areas) was launched in June 2011.
-- Core market focus is on pharma, biotech and translational
medicine centers for developing diagnostic, predictive and
stratification (personalized) biomarkers
-- Multiple custom biomarker discovery, assay development and
biomarker qualification projects delivered and in progress
-- NGS delivers its qualification (testing) services under a
controlled quality environment (document change control system and
standard operating procedures). This is the first phase in an
on-going progression in being able to offer services to a GLP/GCP
standard.
-- Sales in the period were $948,279 (2010: $708,831).
-- Funding of $1.5 million received in January through share
issue.
For further details please contact:
Klaus Rosenau
CEO, NextGen Group PLC +49 160 551 6756
Nicola Marrin/Freddy Crossley
Seymour Pierce Limited +44 20 7107 8000
CEO's Statement
Overview and general information
In Q3 2010 the business initiated an operational restructure of
NGS to bring into the business the technical skill sets necessary
to develop and deliver the products defined within its business
plan. This restructuring was completed in Q1 2011 and has
successfully delivered the first phases of two new assay products
focused on the Oncology and CNS therapeutic areas. These
'off-the-shelf' products for biomarker discovery and/or
qualification have established commercial traction in the first
half of 2011 and are core to the strategy for driving the revenue
growth of the business. The custom protein biomarker discovery,
assay development and qualification (testing) products offered on a
CRO basis remain core to the business.
The Group's chief operations provided through US-subsidiary,
NextGen Sciences Inc (NGS) remain in Ann Arbor, Michigan. Thus the
Group reports in US dollars.
These consolidated, condensed interim financial statements have
been approved for issue by the Board of Directors on 9(th)
September 2011.
Financial review
The loss after tax was $1,591,937 for the six months ended
30(th) June 2011 compared to $1,742,008 for the period ended 30(th)
June 2010. This translates to a loss per share from continuing
operations of $0.0002 for the six month period ended 30(th) June
2011 compared to a loss per share of $0.0004 for the period ended
30(th) June 2010.
Group turnover (excluding turnover for discontinued operations)
for the six months ended 30(th) June 2011 was $948,279 compared to
$708,831 for the period ended 30(th) June 2010, an increase of
33.7%. Total operating charges including Cost of Goods increased by
4.6% from $2,348,247 for the period ended 30(th) June 2010 to
$2,455,178 for the six months ended 30(th) June 2011 (excluding
operating charges for discontinued operations).
In the six months ended 30(th) June 2011 the Company has
completed a placing of new ordinary shares of 0.1 pence each
raising GBP927,410 ($1.5 million). This funding provided general
working capital for the Company, which the Directors believe would
be sufficient for its current requirements.
The shares issued in the year were under a placing of
927,410,000 ordinary shares of 0.1 pence each (the "Placing
Shares") with an existing shareholder in the Company at par value.
In addition, for every Placing Share issued pursuant to the
Placing, the Company has granted a warrant over 1 ordinary share of
0.1 pence each (the "Ordinary Shares") with an exercise price of
0.1 pence per share. The Warrants shall be exercisable for 3 years
from the date of grant.
Biomarker business operating review
The biomarker discovery, assay development and qualification
(testing) products offered on a CRO (Contract Research
Organization) basis remain core to the business. However, as part
of the custom assay development and qualification deals, the
company seeks to negotiate 'freedom to operate' with the assayable
proteins. This enables NextGen to develop its own 'off-the-shelf'
assays for marketing to therapeutically targeted market segments.
Application of this model was demonstrated with the release in
March 2011 of the plasmadiscovery41 assay panel for biomarker
discovery and qualification targeting oncology (prostate,
colorectal and breast cancer as focus areas). Further, the
csfdiscovery43 assay panel for biomarker discovery and
qualification targeting CNS diseases (Alzheimer's, Parkinson's and
multiple sclerosis as focus areas) was launched in June 2011.
The plasmadiscovery41 assay product has achieved significant
commercial traction with the signing of a $700,000 deal for
biomarker qualification (testing) in June 2011.
The business rationale for this strategy is;
1. The company addresses therapeutically relevant 'problems' and
so gains market presence across all segments (pharma, biotech,
academic);
2. Through sample testing, these 'assay panels' attract quick
turnaround revenue;
3. Having its own 'assay panels' proves the technology and
removes the technology hurdle from the selling process and enables
discussion of the solution. Thus the own 'assay panels' drive
custom assay project wins; and
4. Creates a virtuous circle where custom projects negotiated
with freedom to operate enables growth of own 'assay panels' which
enables the company to be more therapeutically relevant,
demonstrate the technology and attract further custom assay
projects.
The company has the infrastructure and expertise necessary to
develop and apply these assays in a commercial CRO setting.
The company now has the operational structure and instrument
infrastructure necessary to take advantage of potential
opportunities arising from the discovery, development and
exploitation of diagnostic, disease progression and patient
stratification (personalization) biomarkers. The Company now has a
track record for delivering the highest quality data to the client
while meeting deadlines and providing excellent support through all
stages of the projects.
The Company's market focus in the immediate term will be on
pharma and biotech companies engaged in the discovery and
development of small molecule and biologic drugs. Further focus
will be on those engaged in Oncology (Breast, Prostate and
Colorectal) and CNS (Alzheimer's, Parkinson's and multiple
sclerosis) therapeutic areas.
Seasonal fluctuations and the market
DNA and protein biomarkers (molecules that provide information
about biological and disease processes, as well as responses to
drugs) have enormous potential in the diagnosis and prognosis of
disease, in the discovery and development of drugs, and in the
development of companion diagnostics to accompany drugs and guide
treatment. They therefore are expected to play a key role in the
development of personalized or stratified medicine, in which the
right patient is given the right medicine at the right time.
Driven by these factors, the biomarker market is growing
strongly, and is anticipated in a 2011 BCC Research report to be
worth almost $30bn by 2015. For NextGen Sciences' areas of
therapeutic focus, the global CNS biomarker market is expected to
reach close to $3.2 billion by 2015 (BCC Research, 2010), and the
global oncology biomarker market is expected to grow to $5.7
billion by 2014 (Goliath, 2010).
Concerning seasonal fluctuations; the demand for biomarker
services increases in the second-half in comparison to the
first-half.
NextGen Group products and services are directly sold to the
pharmaceutical and biotech industry. The trend in declined
productivity and decreased drug approval rates has lead to many
large pharmaceutical and biotech companies to restructure, merge
and/or downsize. The Group's results are dependent on the levels of
outsourcing activities in this sector. This sector and the
diversity of the Group's customer base provide a degree of
protection in an ever changing market.
With increasing consolidation and rationalization with the
pharma and biotech markets, current evidence indicates that
outsourcing from the pharma and biotech markets will grow
significantly and it is a crucial time to become an accepted
partner for these markets. NextGen is aware of the criticality of
the timing now in demonstrating the value of its technology.
Competitive pressures
Biomarkers in the drug discovery, diagnostic and personalized
medicine space traverse a number of technology areas e.g.
proteomics (NextGen's space), genomics, transcriptomics and
metabolonomics. Each of these alternative technologies will be
evaluated by the market and could serve as a substitute to
NextGen's offering and will take market share.
In the proteomic space there are direct competitors employing
the same technology and direct competitors employing alternative
technologies. NextGen is well positioned against same technology
competitors in terms of its ability to demonstrate and deliver
value with our technology. NextGen is the first company using its
technology to release 'off-the-shelf' assays for both plasma and
CSF (cerebrospinal fluid).
Price competition is not seen as a major factor currently
affecting the company's offering and demonstration of the value
proposition will enable high revenue projects. However, as
competition increases, competitive pricing in the market will
emerge. NextGen will continue to offer a premium service to
mitigate against this market pressure whilst maintaining tight
control over its underlying cost base. Pricing pressures can be
mitigated by providing services under a documented quality system
and by ensuring unique and relevant protein content in
'off-the-shelf' assay products.
The biomarker discovery and validation market and its
comprehensive inclusion in the drug discovery path is in the early
stages and NextGen is positioned as one of the early to market
companies.
There are a few direct competitors in the space at present but
many more may be established as the market grows. The Group
actively works with its customers to find new and innovative ways
to meet their changing needs in order to remain at the forefront of
its' chosen market. Our continued investment in people, technology
and logistics is designed to support the Group's competitive
position.
Current Trading and Outlook
In H1 2011, NextGen has completed multiple biomarker projects
and has further projects in the pipeline. The company has begun to
introduce to the market its 'off-the-shelf' assays targeting
Oncology and CNS diseases.
A key element to gaining market presence and overcoming the
technology adoption hurdles is the release and marketing of our own
'assay panels'. It is clear from orders received that the
plasmadiscovery41 assay panel is enabling the business to derive
high margin revenues. We anticipate a similar response to the
csfdiscovery43 product. These products are also enabling the
business to open doors and gain traction within the target market
segments. The key next stage will be to deliver further discovery
and qualification (testing) projects to customers with our
'off-the-shelf' assays' and to publish/present that work in the
public domain so as to clearly demonstrate the value
proposition.
Delivery of our 'off-the-shelf' assays' and demonstration of
value through delivering qualification projects will enable the
company to present a strong argument to the pharmaceutical and
biotech market regarding the 'niche' role the company's technology
can play in their pre-clinical and clinical development programs
and also in their drive to develop companion diagnostics for their
drug products. NextGen's ability to narrow the funnel from large
numbers of potential biomarkers to small, manageable number of
qualified biomarkers in a 6-month time window presents a real
competitive advantage.
This capability also presents NextGen with the opportunity to
identify, play a role in and invest in projects that will develop
and deliver diagnostic, stratification and progression biomarker
assays. NextGen is currently evaluating opportunities to create a
'diagnostics' business that can utilize the technical expertise of
the current business to enable development of an Intellectual
Property (IP) portfolio and to access revenues through licensing of
IP and assays.
Currently, because of the nature and stage of the Group's
business and the services it seeks to provide, the timing of cash
inflows continues to be unpredictable. This, together with the
Group's plans for growth, may necessitate alternative funding
levels and the directors constantly review the need for such
additional funds.
During the period ending 30(th) June 2011, $1.5 million was
raised in order to strengthen the funds in the Company and to allow
the Company to fulfill its commercial strategies, by the issuance
of 927 million shares.
The convertible loan of EUR500,000 originally expired 31(th)
July 2011. The loan period has been extended until 31(th) March
2012.
Consolidated interim income statement
Unaudited Unaudited Audited
6 month 6 month Year to 31
to 30 June to 30 June December
2011 2010 2010
$ $ $
Revenue 948,279 708,831 1,215,554
Cost of sales (683,453) (818,709) (1,229,460)
------------ ------------ ------------
Gross profit/(loss) 264,826 (109,878) (13,906)
Other operating expenses (1,771,725) (1,529,538) (3,193,424)
Impairment of non-financial
assets - - -
------------ ------------ ------------
Loss from operating activities (1,506,899) (1,639,416) (3,207,330)
Finance income - 129 3,482
Finance costs (84,625) (102,721) (137,120)
------------ ------------ ------------
Loss before income tax (1,591,524) (1,742,008) (3,340,968)
Income tax expense (413) - (196)
------------ ------------ ------------
Loss for the period (1,591,937) (1,742,008) (3,341,164)
------------------------------------ ------------ ------------ ------------
Basic loss per share (0.0002) (0.0004) (0.0006)
Basic loss per share from
continuing operations (0.0002) (0.0004) (0.0006)
Consolidated interim statement of comprehensive income
Unaudited Unaudited Audited
Year
6 month 6 month to 31
to 30 to 30
June June December
2011 2010 2010
$ $ $
Net loss attributable to shareholders'
equity (1,591,937) (1,742,008) (3,341,164)
Currency retranslation losses (61,267) (3,994) (80,625)
--------------------------------------- ----------- ----------- -----------
Total recognized income and expense
attributable to shareholder' equity (1,653,204) (1,746,002) (3,421,789)
--------------------------------------- ----------- ----------- -----------
Consolidated interim statement of financial position
Unaudited Unaudited Audited
6 month 6 month Year to 31
to 30 June to 30 June December
2011 2010 2010
$ $ $
Non-current assets
Property, plant and equipment 703,789 285,753 742,440
Goodwill 507,862 507,862 507,862
Investments - 35 35
----------- ----------- -----------
Total Non-current assets 1,211,651 793,650 1,250,337
----------- ----------- -----------
Current assets
Trade and other receivables 982,572 244,758 308,829
Cash and cash equivalents 28,533 1,027,435 21,255
----------- ----------- -----------
Total Current Assets 1,011,105 1,272,193 330,084
----------- ----------- -----------
Total assets 2,222,756 2,065,843 1,580,421
------------------------------- ----------- ----------- -----------
Consolidated interim statement of financial position
(continued)
Unaudited Unaudited Audited
6 month 6 month Year to 31
to 30 June to 30 June December
2011 2010 2010
$ $ $
Equity
Share capital 12,101,225 9,590,302 10,615,514
Share premium account 10,276,362 10,276,362 10,276,362
Merger reserve 10,026,450 10,026,450 10,026,450
Other reserves 1,052,748 938,329 938,329
Foreign currency translation
reserve (658,058) (520,160) (596,791)
Retained earnings (33,472,381) (30,281,288) (31,880,444)
------------- ------------- -------------
Total equity (673,654) 29,995 (620,580)
------------- ------------- -------------
Liabilities
Non-current liabilities
Finance lease 255,998 30,518 296,131
Total non-current liabilities 255,998 30,518 296,131
Current liabilities
Trade payables and other current
liabilities 1,323,627 751,237 770,639
Finance lease 183,840 143,292 147,693
Provisions - 1,162 -
Borrowings 1,132,945 1,109,639 986,538
Total current liabilities 2,640,412 2,005,330 1,904,870
Total liabilities 2,896,410 2,035,848 2,201,001
------------- ------------- -------------
Total equity and liabilities 2,222,756 2,065,843 1,580,421
--------------------------------- ------------- ------------- -------------
Consolidated interim statement of changes in equity
Foreign
currency Total
Share Share Merger Other translation Retained shareholder
Unaudited Capital premium reserve reserves reserve earnings funds
$ $ $ $ $ $ $
Balance at 1
January 2011 10,615,514 10,276,362 10,026,450 938,329 (596,791) (31,880,444) (620,580)
Issue of share
capital 1,485,711 - - - - - 1,485,711
Share-issue
costs - - - - - - -
Share-based
payments - - - 114,419 - - 114,419
Transactions
with owners 1,485,711 - - 114,419 - - 1,600,130
Total
Comprehensive
Income/Loss - - - - (61,267) (1,591,937) (1,653,204)
--------------- ----------- ----------- ----------- ---------- ------------ ------------- ------------
Balance at 30
June 2011 12,101,225 10,276,362 10,026,450 1,052,748 (658,058) (33,472,381) (673,654)
--------------- ----------- ----------- ----------- ---------- ------------ ------------- ------------
Foreign
currency Total
Share Share Merger Other translation Retained shareholder
Unaudited Capital premium reserve reserves reserve earnings funds
$ $ $ $ $ $ $
Balance at 1
January 2010 8,339,409 10,276,362 10,026,450 938,329 (516,166) (28,539,280) 525,104
Issue of share
capital 1,250,893 - - - - - 1,250,893
Share-issue
costs - - - - - - -
Share-based
payments - - - - - - -
Transactions
with owners 1,250,893 - - - - - 1,250,893
Total
Comprehensive
Income/Loss - - - - (3,994) (1,742,008) (1,746,002)
--------------- ---------- ----------- ----------- --------- ------------ ------------- ------------
Balance at 30
June 2010 9,590,302 10,276,362 10,026,450 938,329 (520,160) (30,281,288) 29,995
--------------- ---------- ----------- ----------- --------- ------------ ------------- ------------
Consolidated interim statement of changes in equity
(continued)
Foreign
currency Total
Share Share Merger Other translation Retained shareholder
A Capital premium reserve reserves reserve earnings funds
Audited $ $ $ $ $ $ $
Balance at 1 January 2010 8,339,409 10,276,362 10,026,450 938,329 (516,166) (28,539,280) 525,104
Issue of share capital 2,276,105 - - - - - 2,276,105
Share-issue costs - - - - - - -
Share-based payments - - - - - - -
Transactions with owners 2,276,105 - - - - - 2,276,105
Total Comprehensive Income/Loss - - - - (80,625) (3,341,164) (3,421,789)
---------------------------------------------------- ----------- ----------- ----------- --------- ------------ ------------- ------------
Balance at 31 December 2010 10,615,514 10,276,362 10,026,450 938,329 (596,791) (31,880,444) (620,580)
---------------------------------------------------- ----------- ----------- ----------- --------- ------------ ------------- ------------
Consolidated interim statement of cash flows
Unaudited Unaudited Audited
6 month 6 month Year to 31
to 30 June to 30 June December
2011 2010 2010
$ $ $
Net loss (1,591,937) (1,742,008) (3,341,164)
Taxation 413 - 196
Finance income - (129) (3,482)
Finance cost 84,625 102,721 137,120
Depreciation of property, plant and
equipment 137,229 135,855 303,886
Impairment of intangible assets - - -
Loss/(profit) on sales of property,
plant and equipment - - (63,066)
Profit from disposal of business - - -
Share issue costs 102,364 85,581 257,933
--------------------------------------- ----------- ----------- -----------
Trade and other receivables (673,743) 51,434 (12,637)
Provisions - - (1,162)
Trade payables and other current
liabilities 552,989 76,104 96,666
--------------------------------------- ----------- ----------- -----------
Changes in working capital (120,754) 127,538 82,867
Share option charges 114,419 - -
Effect of exchange rate fluctuations 25,806 (2,406) (40,767)
--------------------------------------- ----------- ----------- -----------
Cash flow from operating activities (1,247,836) (1,292,848) (2,666,477)
--------------------------------------- ----------- ----------- -----------
Taxation (413) - (196)
--------------------------------------- ----------- ----------- -----------
Net cash from operating activities (1,248,249) (1,292,848) (2,666,673)
--------------------------------------- ----------- ----------- -----------
Consolidated statement of cash flows (continued)
Unaudited Unaudited Audited
Year to
6 month 6 month 31
to 30 to 30 June December
June 2011 2010 2010
$ $ $
Net cash from operating activities (1,248,249) (1,292,848) (2,666,673)
Cash flows from investing activities
Interest received - 129 3,482
Purchase of property, plant
and equipment - - (136,009)
Net cash used in investing
activities - 129 (132,527)
----------- ----------- -----------
Cash flows from financing activities
Interest paid (4,965) (82,500) (13,363)
Finance lease paid (21,673) (20,221) (40,387)
Loan interest paid - - (31,890)
Proceeds from borrowings - 1,109,639 1,370,500
Repayment of borrowings - - (475,300)
Capital element of finance
lease rentals (101,182) (181,152) (336,353)
Issues of shares/debentures 1,485,711 1,250,893 2,276,105
Share issue costs recognized
in operating expenditures (102,364) (85,581) (257,933)
----------- ----------- -----------
Net cash used in financing
activities 1,255,527 1,991,078 2,491,379
----------- ----------- -----------
Net increase in cash and cash
equivalents 7,278 698,359 (307,821)
Cash and cash equivalents at
beginning of period 21,255 329,076 329,076
Cash and cash equivalents at
end of period 28,533 1,027,435 21,255
------------------------------------- ----------- ----------- -----------
Notes to the Consolidated Financial Statements
1. Nature of operations and General information
NextGen Group plc and its subsidiaries (together the 'Group')
offers the highest quality proteomic services with a strategic
focus on protein biomarker discovery, assay development, validation
and testing that gives researchers the ability to characterize and
measure proteins in biological samples with accurate, precise and
robust assays.
NextGen Group plc is the Group's ultimate parent company. The
company is incorporated in the United Kingdom. The address of
NextGen Group's registered office is 8th Floor, Kildare House, 3
Dorset Rise, London, EC4Y 8EN. NextGen Group plc's shares are
listed on the AIM Market of the London Stock Exchange.
NextGen Group plc's consolidated interim financial statements
are presented in US Dollars.
The financial information set out in this interim report does
not constitute statutory accounts as defined in Section 434 of the
Companies Act 2006. The Group's statutory financial statements for
the year ended 31 December 2010, prepared under International
Financial Reporting Standards (IFRS), have been filed with the
Registrar of Companies. The auditor's report on those financial
statements was unqualified and did not contain statements under
Section 498(2) or Section 498(3) of the Companies Act 2006.
Basis of preparation
These interim condensed consolidated financial statements have
been prepared using accounting policies consistent with
International Financial Reporting Standards (IFRS) as adopted by
the European Union. This interim report is condensed with respect
to IFRS requirements. As permitted, this interim report has been
prepared in accordance with AIM rules for companies and not in
accordance with IAS 34 "Interim Financial Reporting".
These financial statements have been prepared under the
historical cost convention on a going concern basis, which assumes
the group will continue in operational existence for the
foreseeable future. The key assumptions underpinning the cash flow
forecasts are growth in revenue and the recent injection of further
financial support from within its existing shareholder base. The
accounting policies are the same as those applied by the Group in
its consolidated financial statements for the year ended 31
December 2010 and have been applied consistently throughout the
Group for the purpose of the preparation of these condensed
consolidated interim financial statements.
2. Segment analysis
NextGen's main business is within the Biomarker and Proteomic
Services markets. The activities undertaken are within one business
segment, Biomarker and Proteomic Services. The activities are
carried out by the Company's internal Research and Development
Group.
3. Shares in issue
During the period ending 30(th) June 2011, 927 million shares
were issued in order to strengthen the funds in the Company and to
allow the Company to fulfill it's commercial strategies. Shares
issued for the period to 30(th) June 2011 may be summarized as
follows:
6 months to 30 June 2011, Unaudited Number $
Beginning of the year 6,316,978,644 10,615,514
Share issue 927,410,000 1,485,711
------------------------------------- -------------- -----------
End of period 7,244,388,644 12,101,225
------------------------------------- -------------- -----------
6 months to 30 June 2010, Unaudited Number $
Beginning of year 4,796,978,644 8,339,409
Issue of shares 830,000,000 1,250,893
------------------------------------- -------------- -----------
End of period 5,626,978,644 9,590,302
------------------------------------- -------------- -----------
Year to 31 December 2010, Audited Number $
Beginning of year 4,796,978,644 8,339,409
Issue of shares 1,520,000,000 2,276,105
------------------------------------- -------------- -----------
End of year 6,316,978,644 10,615,514
------------------------------------- -------------- -----------
The share issue yielded $1,485,711 in cash and increased equity
by GBP927,410. The share price at the placing was nominal
value.
4. Loss per share
Basic loss per share is calculated by dividing the profit
attributable to equity holders of the Company by the weighted
average of ordinary share in issue during the period.
A number of shares existed in the period that could potentially
dilute basic earnings per share in the future but were not included
in the calculation of diluted earnings per share since they are
anti-dilutive for all periods.
Unaudited Unaudited Audited
6 month 6 month Year to 31
to 30 June to 30 June December
2011 2010 2010
Operations $ $ $
Loss after tax and earnings
attributable to ordinary
shareholders (1,591,937) (1,742,008) (3,341,164)
Weighted average number of
shares (used for basic
earnings per share) 7,111,169,528 4,801,564,279 5,510,677,274
Diluted weighted average
number of shares (used for
diluted earnings per
share) 12,406,846,439 7,573,405,637 9,014,432,066
Basic and diluted loss per
share (0.0002) (0.0004) (0.0006)
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR ZKLFBFKFBBBF
Nextgen (LSE:NGG)
過去 株価チャート
から 5 2024 まで 6 2024
Nextgen (LSE:NGG)
過去 株価チャート
から 6 2023 まで 6 2024
